ABO Histo-Blood Groups Influence Makeup of Gut Microbiome
|
By LabMedica International staff writers Posted on 01 Feb 2021 |

Image: False-colored electron microscopic image of Bifidobacterium that are one of the major genera of bacteria that make up the gastrointestinal tract and are associated with variants in the lactase gene locus (Photo courtesy of The Keck Science Department of the Claremont Colleges)
Recent genome-wide association studies yielded inconsistent, underpowered and rarely replicated results such that the role of human host genetics as a contributing factor to microbiome assembly and structure remains uncertain.
The intestinal microbiome is implicated as an important modulating factor in multiple inflammatory, neurologic and neoplastic disease. Host genetics, including genes affecting ABO histo-blood groups, may influence the composition of the human gut microbiome.
A large team of scientists at Kiel University (Kiel, Germany) and their colleagues conducted a large genome-wide association study of microbial traits that drew on five cohorts from different regions of Germany that encompassed a total of 8,965 individuals. Following a series of multivariate, univariate abundance, and presence-absence pattern analyses, they uncovered 38 genetic loci associated with the presence of particular bacteria and broad gut microbial community composition.
The team noted an association between variants in the lactase gene locus (LCT) and the genus Bifidobacterium. This association was nominal in four of the five cohorts and stronger in the fifth. They also found an association between a Barnesiella bacterial species and variants in the biliverdin reductase A (BLVRA) gene, which encodes a protein that inhibits toll-like receptor 4 (TLR4) gene expression. The TLR-4 protein is a pattern recognition receptor of the ABO allele.
The scientists investigated ABO histo-blood group associations, including FUT2 secretor status, with microbial features. They found a correlation between non-O blood group and positive secretor status and certain Bacteroides species in four of the five cohorts. Another Bacteroides species, they noted, was also associated with ABO blood status, bolstering the idea that there are histo-blood group-dependent effects on Bacteroides. They further uncovered associations between Faecalibacterium and ABO and between Holdemanella and ABO, as well as an association between FUT2 secretor status and the abundance of Roseburia, independent of ABO type.
Through a Mendelian randomization analysis, the scientists found 19 suggestive microbial effects on host traits, nine of which were tied to Inflammatory Bowel Disease (IBD) or Crohn's disease. One, for instance, suggests that a group of Bacteroides is associated with ABO histo-blood group status and a group of Prevotella appears to protect against Crohn's disease.
Malte Christoph Rühlemann, PhD, the first author of the study, said, “Ultimately, the aim is to identify candidate genes that are investigated in functional studies and that can at one time point be used in a framework of personalized treatment which considers multiple layers of host factors: life history, genetics, the microbiome, and the interaction of them all as target and modulator of treatment success.”
The authors concluded that their findings support the notion that ABO histo-blood group and sector status influences the makeup of the gut microbiome and that they could potentially represent targets for modulating human health and disease. The study was published on January 18, 2021 in the journal Nature Genetics.
Related Links:
Kiel University
The intestinal microbiome is implicated as an important modulating factor in multiple inflammatory, neurologic and neoplastic disease. Host genetics, including genes affecting ABO histo-blood groups, may influence the composition of the human gut microbiome.
A large team of scientists at Kiel University (Kiel, Germany) and their colleagues conducted a large genome-wide association study of microbial traits that drew on five cohorts from different regions of Germany that encompassed a total of 8,965 individuals. Following a series of multivariate, univariate abundance, and presence-absence pattern analyses, they uncovered 38 genetic loci associated with the presence of particular bacteria and broad gut microbial community composition.
The team noted an association between variants in the lactase gene locus (LCT) and the genus Bifidobacterium. This association was nominal in four of the five cohorts and stronger in the fifth. They also found an association between a Barnesiella bacterial species and variants in the biliverdin reductase A (BLVRA) gene, which encodes a protein that inhibits toll-like receptor 4 (TLR4) gene expression. The TLR-4 protein is a pattern recognition receptor of the ABO allele.
The scientists investigated ABO histo-blood group associations, including FUT2 secretor status, with microbial features. They found a correlation between non-O blood group and positive secretor status and certain Bacteroides species in four of the five cohorts. Another Bacteroides species, they noted, was also associated with ABO blood status, bolstering the idea that there are histo-blood group-dependent effects on Bacteroides. They further uncovered associations between Faecalibacterium and ABO and between Holdemanella and ABO, as well as an association between FUT2 secretor status and the abundance of Roseburia, independent of ABO type.
Through a Mendelian randomization analysis, the scientists found 19 suggestive microbial effects on host traits, nine of which were tied to Inflammatory Bowel Disease (IBD) or Crohn's disease. One, for instance, suggests that a group of Bacteroides is associated with ABO histo-blood group status and a group of Prevotella appears to protect against Crohn's disease.
Malte Christoph Rühlemann, PhD, the first author of the study, said, “Ultimately, the aim is to identify candidate genes that are investigated in functional studies and that can at one time point be used in a framework of personalized treatment which considers multiple layers of host factors: life history, genetics, the microbiome, and the interaction of them all as target and modulator of treatment success.”
The authors concluded that their findings support the notion that ABO histo-blood group and sector status influences the makeup of the gut microbiome and that they could potentially represent targets for modulating human health and disease. The study was published on January 18, 2021 in the journal Nature Genetics.
Related Links:
Kiel University
Latest Molecular Diagnostics News
- New Diagnostic Method Detects Pneumonia at POC in Low-Resource Settings
- Blood Immune Cell Analysis Detects Parkinson’s Before Symptoms Appear
- New Diagnostic Marker for Ovarian Cancer to Enable Early Disease Detection

- Urine Test Detects Early Stage Pancreatic Cancer
- Genomic Test Could Reduce Lymph Node Biopsy Surgery in Melanoma Patients
- Urine Test Could Replace Painful Kidney Biopsies for Lupus Patients
- Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
- Mitochondrial DNA Mutations from Kidney Stressors Could Predict Future Organ Decline
- Blood Test Could Predict Bariatric Surgery Outcomes in Teenagers
- ctDNA Blood Test to Help Personalize Postsurgical Colon Cancer Treatment
- AI Powered Blood Test Predicts Suicide Risk in Bipolar Patients
- DNA Sensor Enables Molecular Detection from Single Blood Drop
- DNA-Powered Test Accurately Detects E. Coli Lookalike Bacteria
- World’s Fastest DNA Sequencing Technique to Revolutionize NICU Genomic Care
- Blood Test Uses Cell-Free DNA to Detect ALS Faster and More Accurately
- Multi-Cancer Early Detection Blood Test Increases Cancer Detection
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read moreMolecular Diagnostics
view channel
New Diagnostic Method Detects Pneumonia at POC in Low-Resource Settings
Pneumonia continues to be one of the leading causes of death in low- and middle-income countries, where limited access to advanced laboratory infrastructure hampers early and accurate diagnosis.... Read more
Blood Immune Cell Analysis Detects Parkinson’s Before Symptoms Appear
Early diagnosis of Parkinson’s disease remains one of the greatest challenges in neurology. The condition, which affects nearly 12 million people globally, is typically identified only after significant... Read moreHematology
view channel
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read moreImmunology
view channel
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more
Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Modern cancer immunotherapies rely on the ability of CD8⁺ T cells to rapidly multiply within tumors, generating the immune force needed to eliminate cancer cells. However, the biological triggers behind... Read morePathology
view channel
New Molecular Analysis Tool to Improve Disease Diagnosis
Accurately distinguishing between similar biomolecules such as proteins is vital for biomedical research and diagnostics, yet existing analytical tools often fail to detect subtle structural or compositional... Read more
Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
Diagnosing and monitoring eye and neurodegenerative diseases often requires invasive procedures to access ocular fluids. Ocular fluids like aqueous humor and vitreous humor contain valuable molecular information... Read moreTechnology
view channel
Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
Sorting different cell types—such as cancerous versus healthy or live versus dead cells—is a critical task in biology and medicine. However, conventional methods often require labeling, chemical exposure,... Read more
Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Blood tests remain a cornerstone of medical diagnostics, but traditional imaging and analysis methods can be slow, costly, and reliant on dyes or contrast agents. Now, scientists have developed a real-time,... Read moreIndustry
view channel
Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
QIAGEN (Venlo, Netherlands) has entered into a definitive agreement to fully acquire Parse Biosciences (Seattle, WA, USA), a provider of scalable, instrument-free solutions for single-cell research.... Read more
Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
Puritan Medical Products (Guilford, ME, USA), the world’s most trusted manufacturer of swabs and specimen collection devices, is set to exhibit at AMP2025 in Boston, Massachusetts, from November 11–15.... Read more
Advanced Instruments Merged Under Nova Biomedical Name
Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. This transformation is expected to deliver greater value... Read more








